Day One

Wednesday, August 7, 2024

8:00 am Registration & Morning Refreshments

8:45 am Chair’s Opening Remarks

Securing Bioefficacy & Safety Data to to Streamline Preclinical Translation & Safeguard Regulatory Approval

9:00 am Demonstrating Proof of Bioefficacy to Streamline Preclinical to Clinical

Synopsis

  • Discussing the rationale behind using preclinical models and alternative design of experiment routes to optimally demonstrate bioefficacy
  • Decoding the translation from preclinical to clinical growth studies to understand how to portray growth within experimental design limitations
  • Adopting a multifactorial approach to support the business of proving bioefficacy

9:30 am Case Study: Tapping into the Chinese Market to Inspire Formula Commercialization & Regulatory Strategy

  • Sebastian Finch Senior Regulatory Affairs Specialist, Arla Foods Ingredients

Synopsis

  • Shedding light on the current demographic situation to understand market status and commercial positioning
  • Navigating the complex infant formula registration journey from trial production to commercialization to pin-point successes for business strategies within the Chinese market
  • Eradicating regulatory bottlenecks – from obstacles to approval

10:00 am Navigating the Ever Changing Landscape of Infant Formula & Baby Food Regulatory Requirements

  • Nick Collopy Technical Director of Chemistry, SGS North America Health & Nutrition
  • Sandra Johnson Senior Director of Operations, SGS North America Health & Nutrition

Synopsis

  • SGS scientists will discuss partnering with a commercial testing laboratory to meet formula and baby food safety and regulatory requirements
  • Monitoring the environment
  • Testing the products

10:30 am Speed Networking & Morning Coffee Break

Synopsis

Join your peers in a session of speed networking to foster new relationships

Specializing Functionality to Enhance Quality Profiles Profiles & Translate to End-Users

11:30 am Assessing the Scope & Progress of Novel Bioactives to Move Closer Towards Functional IF & Direct Future Focuses

Synopsis

  • Discussing latest scientific insights on carbohydrates in human milk
  • Discussing the functionality and immune activity of human milk oligosccharides
  • Delving into human milk oligosaccharides and galacto-oligosaccharides to navigate complexities

12:00 pm Evolving Functionality to Meet Infant Formula Requirements Regarding Nutritional Profile & Structures Bridging the Gap to Human Milk

Synopsis

  • Front-loading ingredient-to-formula compatibility to ensure function is retained for desired physiological and cognitive effects
  • Analyzing and assessing functional parameters in alignment with human milk functionality to hone in on desired characteristics
  • Bridging closely towards milk-based flavours and functions to support humanization

12:30 pm Optimizing Infant Gut Health: The Role of Prebiotics & Probiotics

  • Dana Walsh Senior Microbiome Scientist, CosmosID

Synopsis

  • Supplementation of formula to otherwise breastfed infants is associated with changes in microbiome composition
  • HMOs added to formula is associated with a more breastfeeding-like microbiome
  • How birth mode and probiotics impact breastfeeding-associated bifidobacteria communities in early life

12:40 pm Networking Lunch

1:40 pm Delving into Translational Science & to Effectively Communicate the Value of Your Formula & Secure Engagement

  • Ari Brown Chief Medical Advisor, Kabrita USA

Synopsis

  • Demonstrating beneficial effects and value added from formula to consumers to bridge the gap between scientific approach and understanding
  • Streamlining from the clinic to the end-user in order to effectively understand requirements and communicate efficacy
  • Understanding how to prioritize which beneficial effects to communicate in order to support nutritional value added

Leveraging Commercial Factors to Inform Formulae Personalization & Influence Perception

2:10 pm Advocating Nutrition Education to Resonate Closely with Your Market in Light of Commercialization

Synopsis

  • Depicting language nuances and marketing strategy to closely speak to your scientifically driven market for trust-building
  • Leveraging nutrition education and market resonance to identify launch location within timeframes
  • Assessing efficacy claim allowance globally to inform launch location and business gameplan

2:40 pm Roundtable Discussion: Addressing the Gaps in Consumer Awareness & Preferences for Bioactive Ingredients to Drive Innovation & Commercial Expansion

Synopsis

  • Pinpointing current gap between consumer awareness and preferences for bioactive ingredients
  • Discussing the role healthcare professionals play in influencing consumer preferences
  • Discussing commercial approaches to increase consumer preference and influence buying behavior for formulas with bioactive ingredients

3:15 pm Afternoon Break- Energize & Engage!

Synopsis

Network with your peers aside our beneficial light therapy lamps to rejuvenate before the last few sessions.

Optimizing Translation & Communication to Streamline from Science to End-Users

4:00 pm Translating Key Clinical Trial Findings to Support Nutritional & Safety Claims

Synopsis

  • Discussing considerations for design and analysis of a clinical trial for translation of outcomes into impactful claims
  • Utilizing clinical biomarkers and parent-reported symptoms to explore the safety, efficacy, and health impact of an infant formula
  • Understanding the value creation of infant formula trials beyond individual ingredient innovation

4:30 pm Understanding Human Milk as a Biological System to Discuss Implications for Infant Feeding & Breastmilk Ecology: Genesis of Infant Nutrition: “BEGIN”

  • Daniel Raiten Senior Nutrition Scientist, Office of Nutrition Research, National Institutes of Health

Synopsis

  • Addressing unanswered questions regarding chronobiology of human milk to understand infant implications
  • Understanding translational implications regarding infant feeding and human milk biology
  • Discussing donor milk claims and effects in relation to pre-term infants to address where current requirements lie

5:00 pm Chair’s Closing Remarks & End of Conference Day One